Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dynavax Technologies (NQ: DVAX )

9.960 +0.090 (+0.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,214,161
Open 9.920
Bid (Size) 9.460 (30)
Ask (Size) 9.940 (1)
Prev. Close 9.870
Today's Range 9.790 - 10.05
52wk Range 7.260 - 17.48
Shares Outstanding 127,686,631
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The Top 7 Growth Stocks in Biotech
The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term. 
Via InvestorPlace
Dynavax Technologies's Return On Capital Employed Insights
 
Via Benzinga

Performance

YTD
-6.04%
-6.04%
1 Month
-7.18%
-7.18%
3 Month
-8.87%
-8.87%
6 Month
-6.30%
-6.30%
1 Year
-12.71%
-12.71%

More News

Read More
JMP Securities Maintains Market Outperform Rating for Dynavax Technologies: Here's What You Need To Know
Via Benzinga
Dynavax Technologies (DVAX) Q4 2022 Earnings Call Transcript
Via The Motley Fool
Jim Cramer On This Stock Up 2% Over 6 Months: 'You've Got A Real Winner There'
Via Benzinga
Dynavax Technologies (DVAX) Q3 2022 Earnings Call Transcript
Via The Motley Fool
China-Based COVID-19 Shot Neutralizes Omicron Subvariants
Via Benzinga
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
From Clover Biopharmaceuticals
Via Globe NewsWire
The 7 Most Undervalued Long-Term Stocks to Buy in January
Via InvestorPlace
Our 7 Top Small-Cap Stock Picks for 2023
Via InvestorPlace
Dynavax Adjuvant Based COVID-19 Vaccine Lowers The Risk Of Transmission
Via Benzinga
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
From Clover Biopharmaceuticals
Via Globe NewsWire
Earnings Preview For Dynavax Technologies
Via Benzinga
3 Under-the-Radar Small-Cap Stocks With 100% Upside Potential
Via InvestorPlace
Clover Provides Update on 2022 Corporate Milestones
From Clover Biopharmaceuticals
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2022
Via Benzinga
Short Interest Sector Focus: Healthcare Sector
Via Benzinga
Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Why Virios Therapeutics Is Trading Lower By Over 71%, Here Are 55 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Dynavax's Adjuvant Based COVID-19 Shot Shows Robust Immune Response, Safety In Younger Populations
Via Benzinga
Rocket Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
Via Investor's Business Daily
Kura Oncology Stock Joins Rank Of Stocks With RS Ratings Over 90
Via Investor's Business Daily
Dynavax Technologies: Q2 Earnings Insights
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.